Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kodiak Sciences Inc.

3.64
+0.19005.51%
Post-market: 3.640.00000.00%19:55 EDT
Volume:236.06K
Turnover:854.61K
Market Cap:191.11M
PE:-1.00
High:3.70
Open:3.50
Low:3.49
Close:3.45
Loading ...

Company Profile

Company Name:
Kodiak Sciences Inc.
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
108
Office Location:
1200 Page Mill Road,Palo Alto,California,United States
Zip Code:
94304
Fax:
- -
Introduction:
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Directors

Name
Position
Victor Perlroth
Chief Executive Officer, President and Chairman of the Board
Bassil I. Dahiyat
Director
Felix J. Baker
Director
Richard S. Levy
Director
Robert A. Profusek
Director

Shareholders

Name
Position
Victor Perlroth
Chief Executive Officer, President and Chairman of the Board
Hong Liang
Senior Vice President, Discovery Medicine
John A. Borgeson
Senior Vice President and Chief Financial Officer
Jason Ehrlich
Chief Medical Officer and Chief Development Officer